Price (delayed)
$3.35
Market cap
$156.47M
P/E Ratio
33.5
Dividend/share
N/A
EPS
$0.1
Enterprise value
$208.71M
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights
There are no recent dividends present for PBYI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.